Research

We provide a detailed quarterly summary to help investors prepare for their quarterly investor communications as well as identify emerging risk management concerns. We break our quarterly analysis into several areas of interest: performance facts, factor efficacy, the opportunity set, corporate profitability, macro / economic developments, and data from 13F filings and insider transactions.

We have seen a massive deviation in healthcare sector stock performance in 2021. Given the idiosyncratic nature of the sector, meaningful performance deviation is normal. However, this magnitude of performance deviation catalyzed us to look for valuation / growth disconnects and search for opportunities.

The recent market volatility started as a result of opinions over a perceived Fed pivot and the new COVID variant. Corporate commentary generally indicates a slow path toward the resolution of the logistics, transportation, and supply-chain bottlenecks induced by COVID, with many suggesting normalization is expected in the second half of 2022, albeit with some variability depending on product. Given the risk-off / risk-on trading volatility, we took a step back to analyze macro trends and make a data-driven conclusion about the environment.

Our latest market overview: a comprehensive document containing the best of our recent work and up-to-date views.

With lots of questions about the M&A environment, big company break-ups (GE and JNJ), and companies trying to grow, expand margins, or change their multiple, we evaluated the market’s reward and penalties for deals. We found that the initial market reaction to a deal has predictive value, especially for banks and value stocks.

We review investor commentary on our most recent notes and respond to various questions and criticisms.

Ten years ago, there were roughly 30 companies in the US equity market that had a market capitalization greater than $100 billion. At that time, most generalist portfolio managers had formed investment views of these companies, had seen the management teams present or met them over the years, and had a pretty good command of the investment debates for nearly all of these companies. However, today there are 93 companies that have greater than 100b market capitalization – double the number of companies that reached this exclusive barrier three years ago. These names account for roughly 60% of the total market cap. of the SP500. For equity investors whose performance is directly (or even indirectly) benchmarked to the SP500, it has never been more important to be able to generate performance from this exclusive club.

Inflation and speculation were the two most popular questions that surfaced during our dozen meetings last week in the Southeastern part of the US and in NYC. The CPI print this week sparked a fresh round of inflation-related questions from equity investors. Rivian’s IPO has been flagged by many as another example of rampant investor speculation. Given that backdrop, we think two critical questions are: 1. What is the best positioning for tapering, inflation, and the eventual rising of the Federal Fund rates? and 2. How should we think about momentum vs. mean-reversion in more speculative investments?

We explain why we are bullish on US Equities, and identify and address the risks of damaged earnings and valuation. We think US Equities are a treat, not a trick.

Gross profitability is the key investment controversy in today’s market. We reached this conclusion after several months of creating investing frameworks, analyzing risks and sectors, and, more recently, after processing this quarter’s earnings. Here, we show three research analyses we did in the last few months all resulted in the same conclusion – the importance of gross margin expansion for subsequent stock performance.